Archive - US Press Releases

Filter by year

Oncopeptides’ PEPAXTO® Receives a Permanent J-Code, Clarifying Reimbursement Processes in Hospital Outpatient and Physician Office Settings of Care

August 16, 2021
BOSTON— August 16, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established...
Read more

Oncopeptides’ PEPAXTO® Receives a Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

July 13, 2021
BOSTON— July 13, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Centers for Medicare and Medicaid Services (CMS)...
Read more

Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis

July 8, 2021
BOSTON — July 8, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating...
Read more

Phase 3 OCEAN study demonstrates that melphalan flufenamide is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma

May 26, 2021
BOSTON — May 26, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces positive topline results from the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melphalan flufenamide versus pomalidomide...
Read more

Oncopeptides announces three abstracts accepted by the 2021 American Society of Clinical Oncology

May 19, 2021
WALTHAM — May 19, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that three abstracts with data on PEPAXTO®...
Read more

Oncopeptides Completes Patient Enrollment in Phase 2 PORT Study

May 5, 2021
WALTHAM —May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Company has completed patient enrollment in the phase 2 PORT study. The...
Read more

Oncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines

March 22, 2021
BOSTON— March 22, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that PEPAXTO® (melphalan flufenamide) has been added to the Multiple Myeloma Clinical Practice Guidelines of the National...
Read more

Oncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)

March 15, 2021
BOSTON— March 15, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that PEPAXTO® (melphalan flufenamide) is now commercially available and that the first patients are...
Read more

Read the press release on the FDA approval of PEPAXTO

March 1, 2021
WALTHAM — March 1, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),  a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen, in...
Read more